Super-resolution Multispectral Imaging Nanoimmunosensor for Simultaneous Detection of Diverse Early Cancer Biomarkers

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Diagnostics

Background:

• Single biomarker detection is insufficient for accurate cancer diagnosis.
• Blood-based multicancer early detection requires sensitive and specific methods.
• Existing diagnostic kits lack the sensitivity for early-stage cancer detection.

Purpose of the Study:

• To develop a super-resolution multispectral imaging nanoimmunosensor (srMINI) for simultaneous cancer biomarker detection.
• To achieve single-molecule level detection of multiple cancer biomarkers in a single blood sample.
• To enhance the sensitivity and accuracy of early cancer diagnosis through blood-based screening.

Main Methods:

• Development of a srMINI chip utilizing three distinct color-conjugated quantum dots (QDs) and streptavidin.
• Simultaneous detection of three key cancer biomarkers: carcinoembryonic antigen (CEA), C-reactive protein (CRP), and alpha-fetoprotein (AFP).
• Comparison of srMINI chip sensitivity against commercial enzyme-linked immunosorbent assay (ELISA) kits.

Main Results:

• The srMINI chip achieved ultra-high detection sensitivity (0.18-0.5 ag/mL or 1.1-2.6 zM) for CEA, CRP, and AFP.
• Demonstrated 10^8 times higher sensitivity compared to commercial ELISA kits.
• Absence of interfering substrate signals contributed to the enhanced detection performance.

Conclusions:

• The developed srMINI chip enables highly sensitive and accurate simultaneous detection of multiple cancer biomarkers.
• This technology shows significant potential for early cancer diagnosis and large-scale community screening.
• The srMINI chip functions as a promising single-molecule biosensor for precise cancer biomarker analysis.